Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. It offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. The company also sells approximately 60,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, it provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, the company sells hardware products, such as bone and joint fixation, and joint replacement devices; implants; and instruments, which provide for the orthopedic reconstruction of bone in the hand, wrist, elbow, and shoulder, as well as the foot, ankle, and leg below the knee in the extremity bone and joint reconstruction procedures. Integra LifeSciences Holdings Corporation offers its products directly through various sales forces and other distribution channels in the United States, Europe, and internationally. The company was founded in 1989 and is headquartered in Plainsboro, New Jersey.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:IART
Previous Symbol
CUSIP45798520
Phone609-275-0500
Debt
Debt-to-Equity Ratio1.04
Current Ratio3.20
Quick Ratio2.08
Price-To-Earnings
Trailing P/E Ratio24.94
Forward P/E Ratio20.25
P/E Growth1.55
Sales & Book Value
Annual Sales$1.19 billion
Price / Sales3.47
Cash Flow$3.0339 per share
Price / Cash Flow15.95
Book Value$12.26 per share
Price / Book3.95
Profitability
EPS (Most Recent Fiscal Year)$1.94
Net Income$64.74 million
Net Margins5.49%
Return on Equity16.99%
Return on Assets6.18%
Miscellaneous
Employees4,400
Outstanding Shares85,180,000
Market Cap$4.24 billion
OptionableOptionable
Integra Lifesciences (NASDAQ:IART) Frequently Asked Questions
What is Integra Lifesciences' stock symbol?
Integra Lifesciences trades on the NASDAQ under the ticker symbol "IART."
When did Integra Lifesciences' stock split? How did Integra Lifesciences' stock split work?
Shares of Integra Lifesciences split before market open on Tuesday, January 3rd 2017. The 2-1 split was announced on Thursday, December 22nd 2016. The newly created shares were issued to shareholders after the market closes on Wednesday, December 21st 2016. An investor that had 100 shares of Integra Lifesciences stock prior to the split would have 200 shares after the split.
How were Integra Lifesciences' earnings last quarter?
Integra Lifesciences Holdings Corp (NASDAQ:IART) posted its quarterly earnings data on Wednesday, October, 31st. The life sciences company reported $0.59 earnings per share for the quarter, hitting analysts' consensus estimates of $0.59. The life sciences company earned $365.85 million during the quarter, compared to the consensus estimate of $367.89 million. Integra Lifesciences had a net margin of 5.49% and a return on equity of 16.99%. The firm's revenue was up 31.2% compared to the same quarter last year. During the same period last year, the company earned $0.45 earnings per share. View Integra Lifesciences' Earnings History.
When is Integra Lifesciences' next earnings date?
What guidance has Integra Lifesciences issued on next quarter's earnings?
Integra Lifesciences issued an update on its FY18 earnings guidance on Wednesday, October, 31st. The company provided earnings per share guidance of $2.36-2.42 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.40. The company issued revenue guidance of $1.467-1.472 billion, compared to the consensus revenue estimate of $1.49 billion.Integra Lifesciences also updated its FY 2018 guidance to $2.36-2.42 EPS.
What price target have analysts set for IART?
13 brokers have issued 1 year price targets for Integra Lifesciences' shares. Their predictions range from $53.00 to $70.00. On average, they anticipate Integra Lifesciences' share price to reach $61.00 in the next twelve months. This suggests a possible upside of 26.1% from the stock's current price. View Analyst Price Targets for Integra Lifesciences.
What is the consensus analysts' recommendation for Integra Lifesciences?
13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Integra Lifesciences in the last year. There are currently 1 sell rating, 8 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Integra Lifesciences.
What are Wall Street analysts saying about Integra Lifesciences stock?
Here are some recent quotes from research analysts about Integra Lifesciences stock:
- 1. According to Zacks Investment Research, "Integra LifeSciences has underperformed its industry over the past six months. Significant gross margin contractions caused by escalating costs have been a major headwind for the company in the last reported quarter. A tough competitive landscape adds to the woes. On a positive note, solid growth across all business segments has been the key growth catalyst. Integra LifeSciences’ successful progress with its channel expansion strategy and Codman integration buoy optimism. Notably, the company announced plans within Orthopedics and Tissue Technologies segment to expand its sales channel, improve focus and competitiveness and better align the company’s product portfolio with clinical customers. Moreover, the strong investments in research and development is encouraging. However, the company’s reduced 2018 revenue guidance fails to instill confidence in the stock." (12/13/2018)
- 2. BTIG Research analysts commented, "We hosted investor meetings with mgmt. of IART which included President & CEO for multiple days of meetings in the Midwest. Investors were interested in understanding a variety of topics, including the Codman integration, wound, nerve, and dural repair market dynamics, OTT channel changes, as well as other areas of the business. We came away with a clearer picture of IART’s progression toward a higher growth company driven by sales force productivity improvements, product registrations OUS, and a growing pipeline from Codman (a previously underfunded asset). The Street may not be as focused on much of the back-office work that has taken place at IART over FY18 but mgmt. was confident in their ability to meet FY18 organic revenue growth guidance (~5%) and grow above that in FY19 and beyond. Our incremental takeaways are below." (10/11/2018)
- 3. Cantor Fitzgerald analysts commented, ": We maintain our Neutral rating and $59 12-month PT on shares of IART. This morning (7/25), IART reported 2Q rev of $366MM (+3.4% organic), slightly below consensus ($368MM). IART’s 3.4% organic growth was a slight sequential acceleration (+3.0% in 1Q18). (+33%) were in line, as a lower tax rate offset margin weakness relative to expectations. IART reiterated its 2018 top-line organic growth guidance of ~5%, implying 2H18 organic growth of 6.5%, twice that of 1H18." (7/25/2018)
Has Integra Lifesciences been receiving favorable news coverage?
Media coverage about IART stock has been trending somewhat positive recently, InfoTrie reports. The research firm ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Integra Lifesciences earned a daily sentiment score of 1.2 on InfoTrie's scale. They also assigned media headlines about the life sciences company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the next several days.
Who are some of Integra Lifesciences' key competitors?
Some companies that are related to Integra Lifesciences include ResMed (RMD), ABIOMED (ABMD), Teleflex (TFX), DexCom (DXCM), Hill-Rom (HRC), Haemonetics (HAE), Insulet (PODD), ICU Medical (ICUI), Globus Medical (GMED), Penumbra (PEN), Cantel Medical (CMD), Novocure (NVCR), Merit Medical Systems (MMSI), NuVasive (NUVA) and Glaukos (GKOS).
Who are Integra Lifesciences' key executives?
Integra Lifesciences' management team includes the folowing people:
- Mr. Peter J. Arduini, Pres, CEO & Director (Age 53)
- Dr. Richard E. Caruso Ph.D., Founder and Chairman Emeritus (Age 75)
- Mr. Glenn G. Coleman, Corp. VP of International & CFO (Age 50)
- Mr. Daniel L. Reuvers, Corp. VP and Pres of Specialty Surgical Solutions (Age 55)
- Mr. Robert T. Davis Jr., Corp. VP and Pres of Orthopedics & Tissue Technologies (Age 59)
Who are Integra Lifesciences' major shareholders?
Integra Lifesciences' stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (13.68%), Capital Research Global Investors (11.96%), BlackRock Inc. (7.65%), Vanguard Group Inc (7.18%), Vanguard Group Inc. (7.18%) and Janus Henderson Group PLC (2.36%). Company insiders that own Integra Lifesciences stock include Barbara B Hill, Christian S Schade, Daniel L Reuvers, Donald E Morel Jr, Glenn Coleman, James M Sullivan, Jeffrey Mosebrook, Joseph Vinhais, Keith Bradley, Richard D Gorelick, Richard E Caruso and Stuart Essig. View Institutional Ownership Trends for Integra Lifesciences.
Which major investors are selling Integra Lifesciences stock?
IART stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Glenmede Trust Co. NA, Dimensional Fund Advisors LP, Tributary Capital Management LLC, Vanguard Group Inc., Vanguard Group Inc, Morgan Stanley and TIAA CREF Investment Management LLC. Company insiders that have sold Integra Lifesciences company stock in the last year include Christian S Schade, Daniel L Reuvers, Glenn Coleman, Jeffrey Mosebrook, Joseph Vinhais, Keith Bradley, Richard E Caruso and Stuart Essig. View Insider Buying and Selling for Integra Lifesciences.
Which major investors are buying Integra Lifesciences stock?
IART stock was bought by a variety of institutional investors in the last quarter, including Capital World Investors, FMR LLC, Capital Research Global Investors, First Trust Advisors LP, Renaissance Technologies LLC, Deutsche Bank AG, JPMorgan Chase & Co. and JPMorgan Chase & Co.. Company insiders that have bought Integra Lifesciences stock in the last two years include Barbara B Hill and Donald E Morel Jr. View Insider Buying and Selling for Integra Lifesciences.
How do I buy shares of Integra Lifesciences?
Shares of IART can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Integra Lifesciences' stock price today?
One share of IART stock can currently be purchased for approximately $48.39.
How big of a company is Integra Lifesciences?
Integra Lifesciences has a market capitalization of $4.24 billion and generates $1.19 billion in revenue each year. The life sciences company earns $64.74 million in net income (profit) each year or $1.94 on an earnings per share basis. Integra Lifesciences employs 4,400 workers across the globe.
What is Integra Lifesciences' official website?
How can I contact Integra Lifesciences?
Integra Lifesciences' mailing address is 311 ENTERPRISE DRIVE, PLAINSBORO NJ, 08536. The life sciences company can be reached via phone at 609-275-0500 or via email at [email protected]
MarketBeat Community Rating for Integra Lifesciences (NASDAQ IART)
MarketBeat's community ratings are surveys of what our community members think about Integra Lifesciences and other stocks. Vote "Outperform" if you believe IART will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IART will underperform the S&P 500 over the long term. You may vote once every thirty days.
